Publications by authors named "Anton Stuetz"

Claim this Profile
D
Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics.
Petra Doerfler, Nicole Schoefmann, Gabriela Cabral, Wolfgang Bauer, Martin C Berli, Anton Stuetz

J Invest Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Shirley Wang, Sabine Olt, Nicole Schoefmann, Anton Stuetz, Anthony Winiski

Exp Dermatol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Ahmad Jalili, Kirsten D Mertz, Julia Romanov, Christine Wagner, Frank Kalthoff, Anton Stuetz

PLoS One· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemistry of the immunomodulatory macrolide ascomycin and related analogues.
Murty A R C Bulusu, Karl Baumann, Anton Stuetz

Prog Chem Org Nat Prod· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
Hans Skvara, Frank Kalthoff, Josef G Meingassner, Barbara Wolff-Winiski, Heinrich Aschauer, Anton Stuetz

J Invest Dermatol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanical and metabolic injury to the skin barrier leads to increased expression of murine β-defensin-1, -3, and -14.
Kerstin Ahrens, Michael Schunck, Graziella-Francesca Podda, Josef Meingassner, Anton Stuetz

J Invest Dermatol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice.
Simone Meindl, Christine Vaculik, Josef G Meingassner, Gero Kramer, Johnnie Akgün, Anton Stuetz

J Invest Dermatol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes.
Amanda S Büchau, Jürgen Schauber, Thomas Hultsch, Anton Stuetz, Richard L Gallo

J Invest Dermatol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
H Markus Weiss, Marcel Fresneau, Thomas Moenius, Anton Stuetz, Andreas Billich

Drug Metab Dispos· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cornelia Halin, Hermann Fahrngruber, Josef G Meingassner, Guido Bold, Amanda Littlewood-Evans, Anton Stuetz

Am J Pathol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partnership among dermatology, the Society for Investigative Dermatology, and industry: suggestions for change.
Anton Stuetz

J Invest Dermatol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof.
Anthony Winiski, Shirley Wang, Brigitte Schwendinger, Anton Stuetz

Exp Dermatol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro.
Frank S Kalthoff, Anthony Winiski, Petra Fichtinger, Brigitte Schwendinger, Shirley Wang, Anton Stuetz

Int Arch Allergy Immunol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
Anton Stuetz, Karl Baumann, Maximilian Grassberger, Klaus Wolff, Josef G Meingassner

Int Arch Allergy Immunol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis.
Wolfram Hoetzenecker, Simone Meindl, Anton Stuetz, Georg Stingl, Adelheid Elbe-Bürger

J Invest Dermatol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of pimecrolimus vs. corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function.
Mathias B W Krummen, Georg Varga, Meike Steinert, Anton Stuetz, Thomas A Luger

Exp Dermatol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.
Josef G Meingassner, Heinrich Aschauer, Anton Stuetz, Andreas Billich

Exp Dermatol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Wolfram Hoetzenecker, Rupert Ecker, Tamara Kopp, Anton Stuetz, Georg Stingl

J Allergy Clin Immunol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel cyclosporin derivatives featuring enhanced skin penetration despite increased molecular weight.
Andreas Billich, Hermann Vyplel, Maximilian Grassberger, Fritz P Schmook, Andrea Steck, Anton Stuetz

Bioorg Med Chem· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimecrolimus for the treatment of inflammatory skin disease.
Klaus Wolff, Anton Stuetz

Expert Opin Pharmacother· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.
Wolfram Hoetzenecker, Josef G Meingassner, Rupert Ecker, Georg Stingl, Anton Stuetz

J Invest Dermatol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
Andreas Billich, Heinrich Aschauer, András Aszódi, Anton Stuetz

Int J Pharm· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.
Klemens Rappersberger, Michael Komar, Marie-Eve Ebelin, Graham Scott, Pascale Burtin, Anton Stuetz

J Invest Dermatol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis